setback

Servier faces significant clinical setback as billion-dollar muscular dystrophy drug fails pivotal phase 3 trial

The French pharmaceutical giant Servier announced on Tuesday that sevasemten, an experimental therapeutic agent acquired in a high-profile $1.55 billion…